ARVN

AI Memo

Arvinas

As of 2026-08-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and corporate update • 2026-08-04

Base target: $9 / p=50% prob

Biggest risk

The stock remains highly dependent on execution across commercialization and clinical development. Q2 results and management commentary could expose weaker revenue, guidance, demand, cash-flow, or launch trends; the packet lacks those post-print details. Recent officer sales add a modest sentiment headwind.

Invalidation

Break below $6 or thesis failure.

What would change my mind?

ARVN has reached an important validation point with FDA approval of VEPPANU, a licensing arrangement with Rigel, and multiple clinical programs that could generate 2H26 data. The deterministic prior is positive, but the packet does not establish commercial uptake or clinical readout quality.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-04

Base target

p=50%

Bull target

$15

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Officer open-market sales
ARV-027 Phase 1 data in 2H26
VEPPANU commercialization and portfolio execution

BearKey bullets

Cash-flow and financing runway visibility is insufficient in the supplied evidence.
Clinical development, trial readout, regulatory, and execution risk across ARV-102, ARV-806, ARV-393, and ARV-027.
Q2 2026 results, guidance, and management commentary are not included in the packet despite the scheduled August 4 event.

WatchKey bullets

Q2 2026 results and corporate update

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=50%)

Target spread vs base: +66% / -39%

Scenario probabilities

Bull Target: $15 (p=25%)Base Target: $9 (p=50%)Bear Target: $6 (p=25%)

Commentary

Coverage is sparse and primarily consists of filing and earnings-scheduling context. Social sentiment, options skew, short interest, employee sentiment, analyst revisions, and post-print market reaction are unavailable in the packet; missing data is not treated as positive evidence.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Officer open-market sales
ARV-027 Phase 1 data in 2H26
VEPPANU commercialization and portfolio execution

Scenarios

Bull Target (Scenario probability)

$15 / p=25% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$6 / p=25% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 2026 results and corporate update
Management is scheduled to review second-quarter 2026 results and provide a corporate update on August 4, 2026. The packet does not provide the results or guidance outcome yet. [#PR-EARNINGS-2026-07-28]
Prob 100.00% • Move 8.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Officer open-market sales
2026-11-02
The CFO and CMO each reported open-market sales of approximately $0.11 million on May 11, 2026. This is a sentiment headwind but is not evidence about operating performance. [#SEC-FORM4-2026-05-13]
Prob 70% • Move -3% • Priced-in 50%

Long-term Catalysts

Months to a year

ARV-027 Phase 1 data in 2H26
2027-08-04
Arvinas initiated dosing in a Phase 1 healthy-volunteer trial for ARV-027, with single-ascending-dose data anticipated in the second half of 2026. [#SEC-8K-2026-05-12]
Prob 60% • Move 18% • Priced-in 25%
VEPPANU commercialization and portfolio execution
2027-08-04
VEPPANU received FDA approval and exclusive global rights were licensed to Rigel, creating a forward commercial-execution opportunity; actual uptake, revenue contribution, and launch traction remain unconfirmed in the packet. [#SEC-8K-2026-05-12]
Prob 55% • Move 25% • Priced-in 35%

Risks

Cash-flow and financing runway visibility is insufficient in the supplied evidence.
Clinical development, trial readout, regulatory, and execution risk across ARV-102, ARV-806, ARV-393, and ARV-027.
Q2 2026 results, guidance, and management commentary are not included in the packet despite the scheduled August 4 event.
Two officers reported open-market stock sales, which may weigh on sentiment but do not indicate operating deterioration. [#SEC-FORM4-2026-05-13]
VEPPANU approval and licensing do not yet establish commercial uptake, launch execution, or revenue durability.

Peers

Symbol	Summary
AMGN	Large-cap biopharma comparator; useful for sector context but not a close size or development-stage peer.
GILD	Large-cap biopharma comparator with a broader commercial portfolio; direct comparability to ARVN is limited.
REGN	Large-cap innovative biopharma comparator; relevant for sector context, but materially larger and more commercially established.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biopharma comparator; useful for sector context but not a close size or development-stage peer.

GILD

Large-cap biopharma comparator with a broader commercial portfolio; direct comparability to ARVN is limited.

REGN

Large-cap innovative biopharma comparator; relevant for sector context, but materially larger and more commercially established.